Patents by Inventor Nobuhiro Suzuki

Nobuhiro Suzuki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090088419
    Abstract: The present invention provides a compound represented by the formula (I): wherein R1 is a C?1-6#191 alkyl group optionally substituted by a C?3-10#191 cycloalkyl group, R2 is a C?2-6#191 alkyl group, R3 is a hydrogen atom, a C?1-6#191 alkyl group or a halogen atom, and X is —OR6 or —NR4R5 wherein R4 and R6 are each independently a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R5 is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted hydroxy group, or R4 and R5 optionally form, together with the adjacent nitrogen atom, an optionally substituted nitrogen-containing heterocycle, or a salt thereof. The compound of the present invention has a superior peptidase inhibitory action and is useful as an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: February 24, 2006
    Publication date: April 2, 2009
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Hironobu Maezaki, Nobuhiro Suzuki
  • Publication number: 20090012093
    Abstract: The GPR40 receptor function regulator of the present invention, which comprises a compound having an aromatic ring and a group capable of releasing cation is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: November 6, 2003
    Publication date: January 8, 2009
    Inventors: Kohji Fukatsu, Shinobu Sasaki, Shuji Hinuma, Yasuaki Ito, Nobuhiro Suzuki, Masataka Harada, Tsuneo Yasuma
  • Patent number: 7469991
    Abstract: An image forming apparatus includes a counter that counts the accumulated number of predetermined printed recording sheets and an image correction controller that performs an image correction operation when the accumulated number of recording sheets reaches a predetermined number. The image forming apparatus is configured to advance an execution timing of the image correction operation, depending on its predetermined operating status.
    Type: Grant
    Filed: March 23, 2006
    Date of Patent: December 30, 2008
    Assignee: Panasonic Corporation
    Inventors: Nobuhiro Suzuki, Hirobumi Tabata, Akihiko Koshimizu
  • Publication number: 20080319077
    Abstract: The present invention relates to a therapeutic agent for diabetes with sulfonylurea secondary failure, which contains a GPR40 agonist. According to the present invention, a therapeutic agent for diabetes with sulfonylurea secondary failure that affords a superior insulin secretion effect and a superior hypoglycemic effect even in diabetic patients for whom a sulfonylurea compound or a fast-acting insulin secretagogue fails to provide an insulin secretion effect and therefore, fails to provide a sufficient hypoglycemic effect can be provided.
    Type: Application
    Filed: July 26, 2005
    Publication date: December 25, 2008
    Inventors: Nobuhiro Suzuki, Masami Suzuki, Tomoko Asakawa, Osamu Kataoka
  • Patent number: 7410641
    Abstract: The present invention relates to antibodies that bind to the A chain N-terminal peptide. The present invention also relates to (1) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:7 (A chain), (2) a polypeptide containing the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO:8 (B chain), (3) a polypeptide wherein the A and B chains are bonded to each other via disulfide bonds (2 chains) or its salt., (4) DNAs encoding the same, etc. These polypeptides and DNAs encoding the same can be used for the diagnosis, treatment, prevention, etc. for diseases, including abnormalities (e.g., diabetes mellitus, etc.) in metabolic regulation (sugar metabolism, lipid metabolism, etc.) of energy sources such as carbohydrates.
    Type: Grant
    Filed: November 21, 2005
    Date of Patent: August 12, 2008
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasuaki Itoh, Nobuhiro Suzuki, Kazunori Nishi, Hideki Kizawa, Masataka Harada, Kazuhiro Ogi
  • Publication number: 20080108623
    Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4 alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4 alkyl and (4?) a C1-4 alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4 alkoxy-C1-4 alkyl, (3?) a mono-C1-4 alkyl-carbamoyl-C1-4 alkyl, (4?) a C1-4 alkoxy and (5?) a mono-C1-4 alkylcarbamoyl-C1-4 alkoxy, or the like; R3 is a C1-4 alkyl; R4 is a C1-4 alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
    Type: Application
    Filed: August 31, 2007
    Publication date: May 8, 2008
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
  • Publication number: 20080021069
    Abstract: The present invention relates to a GPR40 receptor function regulator comprising a fused imidazole compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof. The GPR40 receptor function regulator is useful as an agent for the prophylaxis or treatment of obesity, hyperinsulinemia, type 2 diabetes and the like.
    Type: Application
    Filed: October 7, 2005
    Publication date: January 24, 2008
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Fumio Itoh, Satoshi Sasaka, Junichi Miyazaki, Nobuhiro Suzuki
  • Patent number: 7300935
    Abstract: The present invention provides a compound represented by the formula: wherein R1 is a C1-4alkyl; R2 is (1) a 5- to 7-membered nitrogen-containing heterocyclic group which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a hydroxy group, (3?) a C1-4alkyl and (4?) a C1-4alkoxy, (2) a phenyl which may have a substituent selected from the group consisting of (1?) a halogen, (2?) a C1-4alkoxy-C1-4alkyl, (3?) a mono-C1-4alkyl-carbamoyl-C1-4alkyl, (4?) a C1-4alkoxy and (5?) a mono-C1-4alkylcarbamoyl-C1-4alkoxy, or the like; R3 is a C1-4alkyl; R4 is a C1-4alkoxy, or the like; n is an integer of 1 to 4; or a salt thereof, as a thienopyrimidine compound having gonadotropin-releasing hormone antagonistic activity.
    Type: Grant
    Filed: January 28, 2004
    Date of Patent: November 27, 2007
    Assignee: Takeda Pharmaceutical Company
    Inventors: Nobuo Cho, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
  • Publication number: 20070259927
    Abstract: The present invention provides an agent for increasing the pancreatic insulin content useful for the treatment of diabetes and the like. In one embodiment, the present invention provides an agent for increasing the pancreatic insulin content, which contains a blood glucose lowering drug that does not stimulate insulin secretion, and a dipeptidyl-peptidase IV inhibitor in combination.
    Type: Application
    Filed: August 25, 2005
    Publication date: November 8, 2007
    Inventors: Nobuhiro Suzuki, Yusuke Moritoh, Masanori Watanabe
  • Publication number: 20070202099
    Abstract: The present invention provides an agent for improving the blood stability of an endogenous ligand, which comprises an antibody that has affinity to the mammalian endogenous ligand but substantially does not neutralize the same, and the above-described agent for the prophylaxis and/or treatment for a disease for which an increase in the blood concentration of the endogenous ligand and/or an prolonged blood half-life is prophylactically or therapeutically effective. Provided that the above-described agent is administered alone to a mammal without co-administering the same or substantially the same compound as the endogenous ligand, the blood stability of the endogenous ligand increases and the receptor activity-regulatory action thereof is enhanced.
    Type: Application
    Filed: March 29, 2005
    Publication date: August 30, 2007
    Inventors: Hiroshi Inooka, Nobuhiro Suzuki, Toshiro Kokubo, Tomofumi Kurokawa
  • Patent number: 7253638
    Abstract: A female connector (F) has a housing (10) with a front end and cavities (11) extend to the front end. Terminal fittings (40) are mounted in the cavities (11). A front wall (50) is mounted on the front end of the housing (10) and is formed with tab insertion holes (51) that can communicate with cavities (11). An operable surface (59A) is exposed at an end surface of the front wall (50). The front wall (50) can be moved from a full locking position to a partial locking position along the front end of the housing (10) by pushing this operable surface (59A). Portions of the end surface of the front wall (50) other than the operable surface (59A) are covered at least partly by an wall (26) of the housing (10) to limit movement of the front wall (50).
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: August 7, 2007
    Assignee: Sumitomo Wiring Systems, Ltd.
    Inventors: Keiichi Nakamura, Ryotaro Ishikawa, Yutaka Noro, Yutaka Kobayashi, Hajime Kawase, Nobuhiro Suzuki
  • Patent number: 7252557
    Abstract: A female connector (F) has a housing (10) with a front end and cavities (11) extend to the front end. Terminal fittings (40) are mounted in the cavities (11). A front wall (50) is mounted on the front end of the housing (10) and is formed with tab insertion holes (51) that can communicate with cavities (11). An operable surface (59A) is exposed at an end surface of the front wall (50). The front wall (50) can be moved from a full locking position to a partial locking position along the front end of the housing (10) by pushing this operable surface (59A). Portions of the end surface of the front wall (50) other than the operable surface (59A) are covered at least partly by an wall (26) of the housing (10) to limit movement of the front wall (50).
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: August 7, 2007
    Assignee: Sumitomo Wiring Systems, Ltd.
    Inventors: Keiichi Nakamura, Ryotaro Ishikawa, Yutaka Noro, Yutaka Kobayashi, Hajime Kawase, Nobuhiro Suzuki
  • Publication number: 20070172194
    Abstract: Image processing device is able to obtain digest video of an actual video with a simple configuration and has processor that generates simulation video data, image display control circuit that converts simulation video data into video signal and displays video signal on a display device, primary buffer that reads the simulation data and stores data of simulation data for a continuous predetermined period of time, wherein the processor detects occurrence of predetermined conditions in simulation data, and a digest replay buffer stores, as one scene of digest data, and data is stored in the primary buffer prior to the time of the occurrence of the predetermined conditions and simulation data for a period of time from when predetermined conditions occurred until when the storage termination conditions are satisfied.
    Type: Application
    Filed: January 19, 2007
    Publication date: July 26, 2007
    Inventor: Nobuhiro Suzuki
  • Publication number: 20070173498
    Abstract: A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R1 and R2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R2 may form a spiro ring together with Ar; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.
    Type: Application
    Filed: September 12, 2005
    Publication date: July 26, 2007
    Inventors: Kaneyoshi Kato, Jun Terauchi, Masaaki Mori, Nobuhiro Suzuki, Yukio Shimomura, Shiro Takekawa, Yuji Ishihara
  • Patent number: 7229986
    Abstract: A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R1 and R2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R1 and R2, together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R2, together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: June 12, 2007
    Assignee: Takeda Pharmaceutical Company Ltd.
    Inventors: Yuji Ishihara, Jun Terauchi, Nobuhiro Suzuki, Shiro Takekawa, Kazuyoshi Aso
  • Publication number: 20070046293
    Abstract: A female connector (F) has a housing (10) with a front end and cavities (11) extend to the front end. Terminal fittings (40) are mounted in the cavities (11). A front wall (50) is mounted on the front end of the housing (10) and is formed with tab insertion holes (51) that can communicate with cavities (11). An operable surface (59A) is exposed at an end surface of the front wall (50). The front wall (50) can be moved from a full locking position to a partial locking position along the front end of the housing (10) by pushing this operable surface (59A). Portions of the end surface of the front wall (50) other than the operable surface (59A) are covered at least partly by an wall (26) of the housing (10) to limit movement of the front wall (50).
    Type: Application
    Filed: November 2, 2006
    Publication date: March 1, 2007
    Applicant: Sumitomo Wiring Systems, Ltd.
    Inventors: Keiichi Nakamura, Ryotaro Ishikawa, Yutaka Noro, Yutaka Kobayashi, Hajime Kawase, Nobuhiro Suzuki
  • Patent number: 7183415
    Abstract: A compound, which has a melanin-concentrating hormone antagonistic action and useful as an agent for preventing or treating obesity, and which is represented by the formula: wherein Ar is a cyclic group optionally having substituent(s); X is a bond or a spacer having a main chain of 1 to 6 atoms; R1 and R2 are the same or different and each is a hydrogen atom or a hydrocarbon group optionally having substituent(s), or R1 and R2 may form, together with the adjacent nitrogen atom, a nitrogen-containing heterocycle optionally having substituent(s); Y is a divalent hydrocarbon group optionally having substituent(s) (except CO); R3 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); and ring A and ring B may further have substituents, and when ring B further has a substituent, the substituent may be linked to R1 to form a ring, or a salt thereof, or a prodrug thereof, is provided.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: February 27, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuji Ishihara, Makoto Kamata, Shiro Takekawa, Nobuhiro Suzuki, Koki Kato
  • Publication number: 20070037807
    Abstract: A compound represented by the formula wherein R1 and R2 are the same or different and each is an optionally substituted hydrocarbon group or an optionally substituted hydroxy group; R3 is an optionally substituted aromatic group; R4 is an optionally substituted amino group; L is a divalent chain hydrocarbon group; Q is a bond or a divalent chain hydrocarbon group; and X is a hydrogen atom, a cyano group, a nitro group, an acyl group, a substituted hydroxy group, an optionally substituted thiol group, an optionally substituted amino group or an optionally substituted cyclic group; provided that when X is an ethoxycarbonyl group, then Q is a divalent chain hydrocarbon group. The compound has a peptidase inhibitory action, is useful as an agent for the prophylaxis or treatment of diabetes and the like, and is superior in efficacy, duration of action, specificity, lower toxicity and the like.
    Type: Application
    Filed: October 29, 2004
    Publication date: February 15, 2007
    Inventors: Satoru Oi, Hironobu Maezaki, Nobuhiro Suzuki
  • Publication number: 20070031416
    Abstract: The present invention intended to provide an agent for preventing/treating Alzheimer's disease. More specifically, the present invention provides an agent for preventing/treating Alzheimer's disease, etc., which comprises a monoclonal antibody specifically reacting with a partial peptide at the C-terminal region of a ?-amyloid or its derivatives.
    Type: Application
    Filed: September 8, 2004
    Publication date: February 8, 2007
    Inventors: Mikio Shoji, Asano Asami, Nobuhiro Suzuki
  • Patent number: 7160887
    Abstract: Compounds of a formula: wherein Ring A represents an optionally-substituted aromatic ring; Ring B represents an optionally-substituted cyclic hydrocarbon group; Z represents an optionally-substituted cyclic group; R1 represents a hydrogen atom, an optionally-substituted hydrocarbon group, an optionally-substituted heterocyclic group, or an acyl group; R2 represents an optionally-substituted amino group; D represents a chemical bond or a divalent group; E represents —CO—, —CON(Ra)—, COO—, N(Ra)CON(Rb)—, —N(Ra)COO—, —N(Ra)SO2—, N(Ra)—, —O—, —S—, —SO— or —SO2— (in which Ra and Rb each independently represent a hydrogen atom or an optionally-substituted hydrocarbon group); G represents a chemical bond or a divalent group; L represents (1) a chemical bond or (2) a divalent hydrocarbon group optionally having from 1 to 5 substituents selected from; (i) a C1-6 alkyl group, (ii) a halogeno-C1-6 alkyl group, (iii) a phenyl group, (iv) a benzyl group, (v) an optionally-substituted amino group, (vi) an optionally
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: January 9, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Satoru Oi, Nobuhiro Suzuki, Kazuyoshi Aso, Yoshihiro Banno